Polyarginine-mediated protein delivery to dendritic cells presents antigen more efficiently onto MHC class I and class II and elicits superior antitumor immunity.

[1]  Youjin Lee,et al.  Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors , 2005, The Journal of experimental medicine.

[2]  S. Rosenberg,et al.  CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells , 2005, The Journal of Immunology.

[3]  D. Gabrilovich.  Mechanisms and functional significance of tumour-induced dendritic-cell defects , 2004, Nature Reviews Immunology.

[4]  R. Medzhitov,et al.  Toll-dependent control mechanisms of CD4 T cell activation. , 2004, Immunity.

[5]  S. Rosenberg,et al.  Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.

[6]  S. Akira,et al.  Expression of Toll-Like Receptor 4 on Dendritic Cells Is Significant for Anticancer Effect of Dendritic Cell-Based Immunotherapy in Combination with an Active Component of OK-432, a Streptococcal Preparation , 2004, Cancer Research.

[7]  D. Pardoll,et al.  Persistent Toll-like receptor signals are required for reversal of regulatory T cell–mediated CD8 tolerance , 2004, Nature Immunology.

[8]  J. Berzofsky,et al.  Immunoregulatory T cells in tumor immunity. , 2004, Current opinion in immunology.

[9]  P. Robbins,et al.  Evaluation of peptide-mediated transduction in human CD34+ cells. , 2004, Human gene therapy.

[10]  Ronald T. Raines,et al.  Pathway for polyarginine entry into mammalian cells. , 2004, Biochemistry.

[11]  C. Leclerc,et al.  New tools for antigen delivery to the MHC class I pathway. , 2004, Trends in immunology.

[12]  B. Franc,et al.  Breaching biological barriers: protein translocation domains as tools for molecular imaging and therapy. , 2003, Molecular imaging.

[13]  S. Nakahara,et al.  Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide. , 2003, Cancer research.

[14]  K. Chamoto,et al.  A novel tumor-vaccine cell therapy using bone marrow-derived dendritic cell type 1 and antigen-specific Th1 cells. , 2003, International immunology.

[15]  T. Blankenstein,et al.  The role of IFN-γ in tumor transplantation immunity and inhibition of chemical carcinogenesis , 2003 .

[16]  M. Udey,et al.  Dendritic cells transduced with TAT protein transduction domain‐containing tyrosinase‐related protein 2 vaccinate against murine melanoma , 2003, European journal of immunology.

[17]  R. Steinman,et al.  The use of dendritic cells in cancer immunotherapy. , 2003, Current opinion in immunology.

[18]  G. Mufti,et al.  High efficiency protein transduction of quiescent and proliferating primary hematopoietic cells. , 2003, Journal of biochemical and biophysical methods.

[19]  Vladimir P Torchilin,et al.  Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome–DNA complexes , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[20]  T. Eberlein,et al.  Induction of Antigen-Specific CTL by Recombinant HIV Trans-Activating Fusion Protein-Pulsed Human Monocyte-Derived Dendritic Cells 1 , 2003, The Journal of Immunology.

[21]  D. Ridgway.  The First 1000 Dendritic Cell Vaccinees , 2003, Cancer investigation.

[22]  S. Futaki.  Arginine-rich peptides: potential for intracellular delivery of macromolecules and the mystery of the translocation mechanisms. , 2002, International journal of pharmaceutics.

[23]  Simon C Watkins,et al.  Efficiency of Protein Transduction Is Cell Type-dependent and Is Enhanced by Dextran Sulfate* , 2002, The Journal of Biological Chemistry.

[24]  F. Tanaka,et al.  Effective strategy of dendritic cell-based immunotherapy for advanced tumor-bearing hosts: the critical role of Th1-dominant immunity. , 2002, Molecular cancer therapeutics.

[25]  P. Hwu,et al.  Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells. , 2002, The Journal of clinical investigation.

[26]  M. Udey,et al.  Dendritic Cells Transduced with Protein Antigens Induce Cytotoxic Lymphocytes and Elicit Antitumor Immunity1 , 2002, The Journal of Immunology.

[27]  E. Gilboa,et al.  Influence of CD4 T cells and the source of major histocompatibility complex class II‐restricted peptides on cytotoxic T‐cell priming by dendritic cells , 2002, Immunology.

[28]  J. Bahn,et al.  Transduction of human catalase mediated by an HIV-1 TAT protein basic domain and arginine-rich peptides into mammalian cells. , 2001, Free radical biology & medicine.

[29]  H. Inokuchi,et al.  Protein Transduction Domain of HIV-1 Tat Protein Promotes Efficient Delivery of DNA into Mammalian Cells* , 2001, The Journal of Biological Chemistry.

[30]  K. Pattabiraman,et al.  The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[31]  J. Rothbard,et al.  Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation , 2000, Nature Medicine.

[32]  K. Tamada,et al.  Local injections of OK432 can help the infiltration of adoptively transferred CD8+ T cells into the tumor sites and synergistically induce the local production of Th1-type cytokines and CXC3 chemokines , 2000, Cancer Immunology, Immunotherapy.

[33]  K. Hruska,et al.  Protein transduction: unrestricted delivery into all cells? , 2000, Trends in cell biology.

[34]  T. Blankenstein,et al.  CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. , 2000, Immunity.

[35]  D. Carbone,et al.  Clinical significance of defective dendritic cell differentiation in cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  Ralph Weissleder,et al.  Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells , 2000, Nature Biotechnology.

[37]  S. Dubinett,et al.  Tumors Promote Altered Maturation and Early Apoptosis of Monocyte-Derived Dendritic Cells1 , 2000, The Journal of Immunology.

[38]  A. Ohta,et al.  Distinct Role of Antigen-Specific T Helper Type 1 (Th1) and Th2 Cells in Tumor Eradication in Vivo , 1999, The Journal of experimental medicine.

[39]  S. Rosenberg,et al.  High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. , 1999, Journal of immunology.

[40]  D. Pardoll,et al.  The role of CD4+ T cell responses in antitumor immunity. , 1998, Current opinion in immunology.

[41]  K. Tamada,et al.  Antitumor vaccination effect of dendritic cells can be augmented by locally utilizing Th1-type cytokines from OK432-reactive CD4+ T cells , 1998, Cancer Immunology, Immunotherapy.

[42]  J. Yewdell,et al.  Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. , 1997, Immunity.

[43]  Y. Kong,et al.  Local injection of OK432 can augment the TH1‐type T‐cell response in tumor‐draining lymph node cells and increase their immunotherapeutical potential , 1997, International journal of cancer.

[44]  E. Gilboa,et al.  Induction of antitumor immunity using bone marrow-generated dendritic cells. , 1996, Journal of immunology.

[45]  Peter Walden,et al.  Exact prediction of a natural T cell epitope , 1991, European journal of immunology.

[46]  C. Reis e Sousa,et al.  Dendritic cells: immunobiology and cancer immunotherapy. , 2004, Immunity.

[47]  Laurence Zitvogel,et al.  Antigen presentation and T cell stimulation by dendritic cells. , 2002, Annual review of immunology.

[48]  G. Waksman,et al.  Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo. , 2001, Cancer research.

[49]  S. Dowdy,et al.  Transduction of full-length Tat fusion proteins directly into mammalian cells: analysis of T cell receptor activation-induced cell death. , 2000, Methods in enzymology.

[50]  W. Betz,et al.  Monitoring secretory membrane with FM1-43 fluorescence. , 1999, Annual review of neuroscience.